سعر بريفينار 13 سرنجة معبأة حقن عضل 2024

Pneumococcal 13-valent conjugate vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F conjugated to CRM197, adsorbed on aluminium phosphate), 0.5 ml suspension for intramuscular injection in a pre-filled syringe.

• Active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents aged 6 weeks to 17 years.Population: Infants, children and adolescents 6 weeks-17 yearsEuropean Medicines Agency (EPAR product information)
• Active immunisation against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults aged 18 years and older, including the elderly.Population: Adults >=18 yearsEuropean Medicines Agency (EPAR product information)

• Hypersensitivity to the active substances, to any excipient, or to diphtheria toxoid.International label, same product · European Medicines Agency (EPAR product information)

• Postpone vaccination in acute severe febrile illness (a minor infection is not a reason to defer).International label, same product · European Medicines Agency (EPAR product information)
• Appropriate treatment must be available for rare anaphylactic reactions. Do not give intramuscularly to people with thrombocytopenia or coagulation disorders that contraindicate IM injection.International label, same product · European Medicines Agency (EPAR product information)
• Protects only against the 13 included serotypes; immunocompromised individuals may have a reduced antibody response.International label, same product · European Medicines Agency (EPAR product information)

• No data on use in pregnant women; use of Prevenar 13 should be avoided during pregnancy.International label, same product · European Medicines Agency (EPAR product information)
• It is unknown whether the vaccine is excreted in human milk.International label, same product · European Medicines Agency (EPAR product information)